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ELECTRONIC LETTER
Chinese patients with sporadic Hirschsprung’s disease
are predominantly represented by a single RET haplotype
M-M Garcia-Barcelo´, M-H Sham, V C-H Lui, B L-S Chen, Y-Q Song, W-S Lee, S-K Yung, G Romeo,
P K-H Tam
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H
irschsprung’s disease is a developmental disorder
characterised by the absence of ganglion cells in the
nerve plexuses of the lower digestive tract. The
Hirschsprung phenotype is variable and can be classified
into two groups: SSA, or short segment aganglionosis, which
includes patients with aganglionosis as far as the rectosig-
moid junction; and LSA, or long segment aganglionosis,
which includes patients with aganglionosis beyond the
rectosigmoid junction. The condition presents in the neonatal
period as a failure to pass meconium, chronic severe con-
stipation, colonic distension, secondary electrolyte distur-
bances, and sometimes enterocolitis and bowel perforation.
The estimated population incidence is 1/5000 live births,
although this is a representative value. The highest incidence
is in Asian populations (2.8 per 10 000 life births) and the
lowest in Hispanics (1 per 10 000 life births).1 The male to
female (M:F) ratio is approximately 4:1 for SSA patients and
approximately 1:1 for LSA patients.1 Approximately 20% of
cases are familial. The recurrence risks for siblings of SSA
variant probands ranges between 1.5% and 3.3%, while the
risks for those of LSA variant probands varies from 2.9% to
17.6%.1 Hirschsprung’s disease is often associated with
chromosomal abnormalities, with other neurodevelopmental
disorders such as Waardenburg syndrome type 4, and with a
variety of additional isolated anomalies and syndromes.1 2
The disease has a complex genetic aetiology, and many
studies indicate the receptor tyrosine kinase gene (RET) as
the major susceptibility gene for Hirschsprung’s disease.1–14
RET mutations are also associated with multiple endocrine
neoplasia type 2 (MEN2),15 and medullary thyroid carci-
noma.16 Papillary thyroid carcinoma is associated with RET
somatic rearrangements.17
Mutations in the RET gene account for up to 50% of the
familial cases and anywhere between 7% and 35% of the
sporadic cases, and they lack genotype–phenotype correla-
tion.5–14 Other Hirschsprung genes identified so far mainly
code for protein members of interrelated signalling pathways
involved in the development of enteric ganglia: RET,
endothelin receptor B (EDNRB),18–24 and the transcriptional
regulator SOX10 signalling pathways.25 26 Mutations in the
SIP1 gene have been found to cause syndromic
Hirschsprung’s disease.27 These genes account for a small
proportion of patients with this disorder (7%). Approximately
50% of affected individuals do not have mutations in the
Hirschsprung genes.1 However, genetic linkage analyses in
both LSA and SSA variant families repeatedly implicate the
RET gene as a major susceptibility locus,28 29 even though the
evidence of those linkage analyses is not reflected in the RET
mutation status of many patients in whom RET coding region
mutations were not found.
There are several possible explanations for the complex
genetic aetiology of Hirschsprung’s disease:
N mutations in as yet unidentified genes;
N mutations in RET non-coding region that remain to be
found;
N RET could be under epistatic regulation, and the interac-
tion of several unlinked genes is required to produce the
phenotype23 24 28 29;
N RET specific SNPs, or a combination of these, could act as
low susceptibility alleles or as factors modifying the
phenotypic expression, or even be in linkage disequili-
brium with an unknown susceptibility locus.30–33
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: HWE, Hardy-Weinberg equilibrium; LSA, long segment
aganglionosis; NT, chromosomes not transmitted; SNP, single nucleotide
polymorphism; SSA, short segment aganglionosis; TDT, transmission
disequilibrium test; TR, chromosomes transmitted
Key points
N Hirschprung’s disease has a complex genetic aetiol-
ogy, with RET being the major gene. This study was
initiated to evaluate the RET haplotypes associated with
the disease in the Chinese population. It was hypothe-
sised that if the Hirschsprung phenotype is also related
to the particular combinations of RET single nucleotide
polymorphisms (SNPs), and if the incidence of those
SNPs differs among populations, identification of those
population specific alleles and haplotypes contributing
to disease would help elucidate the molecular basis
underlying Hirschsprung’s disease.
N The transmission disequilibrium test (TDT) and standard
case–control statistics were used for comparison of RET
haplotypes. Haplotypes were also compared between
patients with different Hirschsprung’s disease pheno-
types and RET mutation status.
N One main haplotype—allele A of c135G.A(A45A),
allele G of c1296G.A(A432A), and allele G of
c2307T.G(L769L)—represented 66% of the patients
with Hirschsprung’s disease (A-G-G, x2 = 22.23;
p = 0.000002). Allele A of c1296G.A and haplotypes
comprising it were associated with the more severe
manifestations of the disease (p = 0.000074), regard-
less of the RET mutation status.
N The finding of A-G-G in 66% of Chinese patients with
Hirschsprung’s disease indicates that they share the
same genetic aetiology.
N These findings are relevant to Hirschsprung’s disease
disease risk and to gene mapping, particularly for
genome-wide linkage disequilibrium testing through
the use of SNP markers.
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Genetic differences in risk factors among human popula-
tions derive mainly from gradations in allele frequencies
rather than from distinctive ‘‘diagnostic’’ genotypes. Thus the
structure of human populations is relevant in various
epidemiological contexts, and to our knowledge, RET poly-
morphism studies have only been conducted in white
populations. RET SNP profiling, together with the investiga-
tion of RET alleles that could act as susceptibility factors in
our population, will help to provide a better understanding of
the mechanism of Hirschsprung’s disease. In this paper, we
present the first study on the RET polymorphisms found in
Chinese patients with Hirschsprung’s disease, together with
their genotype and haplotype distributions.
METHODS
Patients and controls
Eighty seven ethnic Chinese patients diagnosed with sporadic
Hirschsprung’s disease between January 1984 and April 2003
were included in the study. The diagnosis was based on
histological examination of either biopsy or surgical resection
material for the absence of enteric ganglia. Using polymerase
chain reaction (PCR) amplification and direct sequencing, we
screened the 21 exons of the RET gene, including intron/exon
boundaries, from 87 patients, 52 available parents, and 100
ethnically matched controls. All individuals assented to the
molecular analyses. The primers and PCR conditions used
were as previously described.34 For exon 21, we generated the
following pair of primers: 59-AAAGGGAGTTTTGCCAAGGCC-
39 (forward) and 59-TTTAAGTCTGAAGAGCAGGC-39
(reverse), which yielded a 157 base pair (bp) product.
Statistical analysis
The allele frequencies in patients and controls were calcu-
lated from the genotype frequencies and compared by the x2
test or Fisher’s exact test when an expected cell value was
less than 5. Haplotype frequencies were estimated, using the
EM algorithm as implemented in the EH program.35 EH is a
linkage utility program to test and estimate linkage dis-
equilibrium between different markers or between a disease
locus and markers. To test whether haplotype frequencies
were significantly different between cases and controls, we
did three separate analyses using the EH program: on the
case subjects alone, on the control subjects alone, and on
the combination of case and controls subjects. The three
log-likelihoods obtained (lnLcase, lnLcontrol, and lnLcombined)
were used to calculate the relevant statistical test:
T = [ln(Lcase)+ln(Lcontrol)2ln(Lcombined)]. Twice this value
gives an approximate x2 distribution with a number of
degrees of freedom (df) equal to the number of haplotypes
estimated under the hypothesis that allelic association is
allowed. The EH program, which assumes Hardy-Weinberg
equilibrium, was also used to estimate linkage disequilibrium
between polymorphisms. GENEHUNTER (version 2.1) was
used to undertake a transmission disequilibrium test (TDT)
for marker haplotypes. Probability (p) values were considered
suggestive at a level of ,0.05, and significant at a level of
,0.005, to allow for the testing of 13 partially correlated
markers.
RESULTS
RET mutations and polymorphisms
Sequencing analyses showed that 16 patients (18.4%) had
potentially disease causing mutations in the RET gene
(Garcia-Barcelo´ M-M et al, unpublished data). Classification
of the patients according to the length of the aganglionic
segment (phenotype) and the RET mutation status is shown
in table 1.
Thirteen single nucleotide polymorphisms (SNPs) were
found, of which five were new. The frequencies of these five
new polymorphisms were ,5% in both patients and controls,
and are likely to be private to our population, thus indicating
ethnic differences in the RET-SNP profile. Except for
c135G.A(A45A), the rest of the loci were in Hardy-
Weinberg equilibrium (HWE) when checked for the total
population; c135G.A(A45A) deviated slightly from HWE in
the total population but HWE was conserved in the control
population. The frequencies of the SNPs and their compar-
ison with those reported for white subjects are shown
in table 2.36 37 The alleles associated (p,0.05) with
Table 1 Classification of the patients
according to the length of the aganglionic
segment (phenotype) and the RET mutation
status
Phenotype With mutation Without mutation
LSA (n = 14 6 (37.5%) 8 (11.3%)
SSA (n = 73) 10 (62.5%) 63 (88.7%)
(n = 16) (n = 71)
LSA, long segment aganglionosis; SSA, short segment
aganglionosis.
Table 2 Allele frequencies of RET single nucleotide polymorphisms in 87 sporadic Chinese cases of Hirschsprung’s disease
and 100 ethnically matched controls
Exon Nucleotide change Codon
Frequency of the variant
allele (%) Statistic
Frequency of the variant allele (%)
Spanish* German
Controls (100) Patients (87) x2 p Value
Controls v patients
(x2; p value)
Controls v patients
(x2; p value)
– IVS1-17 T.G (new) – 0 1.1 1.15 0.28 ND ND
2 c129 C.G (new) D43E 1 0 0.87 0.34 ND ND
2 c135 G.A A45A 41 73 38.62 ,0.0001 16 v 59 (62.5; ,0.0001) 23 v 73.4 (93.1; ,0.001)
2 c200 G.A (new) R67H 2.5 0.5 2.18 0.14 ND ND
– IVS2+9 G.A – 10.5 5.1 3.60 0.06 ND ND
3 c375 C.A V125V 0.5 0.5 0.01 0.92 3 v 7 (F; 0.15) 1.9 v 2.4 (0.12; 0.7)
7 c1296 G.A A432A 21 12 5.30 0.02 30 v 21.8 (F; 0.14) 27.6 v 25.8 (0.14; 0.7)
7 c1465 G.A (new) D489N 2 3.4 0.75 0.39 ND ND
11 c2071 G.A G691S 10.5 4.5 4.53 0.03 23.5 v 12.5 (5.4; 0.02) 20.2 v 10.5 (5.8; 0.016)
11 c2037 C.T (new) P679P 0.5 0.5 0.01 0.92 ND ND
13 c2307 T.G L769L 49 75.2 28.05 ,0.0001 14 v 30.5 (12; ,0.0001) 23.7 v 42.7 (15.5; ,0.001)
14 c2508 C.T S836S 0 0 2 2 4 vs. 2.3 (F; 0.54) 3.6 v 0 (4.8; 0.032)
15 c2712 C.G S904S 10.5 4.5 4.53 0.03 23.5 v 12.5 (5.4; 0.02) 20 v 11.3 (4.5; 0.03)
*Borrego et al, 1999; Fitze et al, 1999.
F, Fisher’s exact test; ND, not described;
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Hirschsprung’s disease in our population were allele A of
c135G.A(A45A), allele A of c1296G.A(A432A), allele G of
c2307T.G(L769L), allele G of c2712C.G(S904S), and allele
A of c2071G.A(G691S). Association of allele A of
c135G.A(A45A), allele A of c1296G.A(A432A), and allele
G of c2307T.G(L769L) was independently tested by TDT
(table 3). The allele A of c1296G.A(A432A) was significantly
underrepresented in Chinese patients.
RET genotype distribution
Forty two different genotypes encompassing the 13 RET SNPs
found were observed among cases and controls (not shown).
The overall genotype distribution differed significantly
between cases and controls (x2 = 79.08; 41 df;
p = 0.000327). One to one genotype comparisons showed
that four main genotypes (of 42) showed a significant
difference between patients and controls (genotypes 1 to 4 in
table 4). The most common disease associated RET genotype
(50.6%; genotype 1) was that homozygous for both allele A of
c135G.A(A45A) and allele G of c2307T.G(L769L), and
wild-type for the rest of polymorphisms found. Genotypes
heterozygous for these two polymorphisms (genotypes 2 and
8) were instead overrepresented in the control population.
Identification of the main RET haplotype in Chinese
patients with Hirschsprung’s disease
We constructed the haplotypes comprising the three most
significantly disease associated RET SNPs in our population
(c135G.A(A45A), c1296G.A(A432A), and c2307T.G(L769L))
and on the basis of published reports.36 37 Significant
differences were observed in the global haplotype distribution
between patients and controls (x2 = 42.46; p,0.00001 for
haplotypes; x2 = 57.52; p,0.00001 for genotypes). One to one
comparison revealed significant differences between patients
and controls for haplotypes A-G-G, G-G-T, and G-A-T. A TDT
test done in 52 parent–proband trios confirmed the results
(table 5). A-G-G was the most common case haplotype in our
population, with an estimated frequency of 66%.
RET-SNPs and RET haplotypes in different
Hirschsprung phenotypes
To investigate whether RET-SNPs are associated with a
particular Hirschsprung phenotype, we compared the allelic
distribution of the polymorphisms described above between
patients with long/total segment aganglionosis (LSA) and
patients with short segment aganglionosis (SSA), and also
between patients harbouring mutations in RET or not. Only
allele A of c1296G.A(A432A) was significantly under-
represented in SSA patients (table 6). TDT, done in 45
parent–proband trios with SSA, showed that allele G was the
most frequently transmitted allele (TR:NT 22:6; x2 = 9.14;
p = 0.002). None of the SNPs revealed statistically significant
differences in frequencies between patients with RET muta-
tion and those without (table 6).
Three-loci haplotype
To test the previously observed association of allele A of
c1296G.A(A432A) with LSA, we investigated whether the
haplotype distribution differed between LSA and SSA
patients. Allele A had already been found significantly
underrepresented when all patients with Hirschsprung’s
disease were compared with controls, and from these
observations a protective role for this allele seemed plausible.
However, the frequency of allele ‘‘A’’ in patients affected with
LSA, although not statistically significant, was higher than
for the same allele in controls, which is at odds with a
Table 3 Transmission disequilibrium test (TDT) by individual polymorphic locus
TDT
Codon SNP (allele) TR NT x2 p Value
A45A c135G.A (A) 49 12 22.44 0.000002
A432A c1296G.A (A) 9 24 6.82 0.009
L769L c2307T.G (G) 53 15 21.24 0.000004
NT, chromosomes not transmitted; SNP, single nucleotide polymorphism; TR, chromosomes transmitted
Table 4 Frequency of RET genotypes in patients with Hirschsprung’s disease and controls
Genotype`1
A45A V125V A432A
G691S L769L
Chinese patients
(n = 87) Chinese
controls
(n = 100)
(%) x2 p Value
Spanish
patients
(n = 62)*
(%)
Spanish
controls
(n = 65)
(%)c135 G.A c375 C.A c1296 G.A
c2071
G.A
c2307
T.G (n) (%)
1 AA CC GG CC GG 44 50.6 12 29.81 ,0.0001 4.8 (CC) 1.5
2 GA CC GG CC TG 5 5.7 26 11.83 ,0.0001 3.2 (AC) 0.0
3 GG CC GA CC TT 0 0.0 5 4.47 0.03 4.8 (AD) 18.5
4 GG CC GG CC TG 1 1.1 8 4.77 0.02 0.0 (AL) 1.5
5 AA CC GG CC TT 0 0 0 – – 11.3 (BB) 0.0
6 AA CC GG CC TG 3 3.5 1 1.33 0.24 9.7 (BC) 3.1
7 GA CC GG CC GG 4 4.6 2 1.01 0.31 0.0 (CL) 0.0
8 GA CC GA CC TG 3** 3.5 9 2.39 0.12 11.3 (AF/CD) 0.0
9 GA CA GG CC TT 0 0 0 – – 9.7 (BH) 0.0
10 GA CC GA CC TT 0 0 2 1.76 0.18 6.5 (BD) 0.0
11 GG CC GG CC TT 5 5.7 4 0.31 0.57 0.0 (AA) 12.3
Rest of genotypes combined 22 25.3 31 5.9 0.01 38.7 63.1
*Borrego et al, 2000.
Capital letters in brackets represent genotypes as designated in Borrego et al, 2000.
`Only those genotypes with significant differences in frequencies between both populations are represented.
1In bold, genotypes with statistically significant differences between Chinese patients and controls.
One individual was TG for IVS1-17 T.G and another individual was GA for c1465 G.A D489N.
**Two individuals were GA for IVS2+9 G.A.
One individual was GA for IVS2+9 G.A and another individual was GA for c1465 G.A D489N.
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protective role. This suggested that the association of allele A
with LSA was in combination with other polymorphisms
within RET.
Global haplotype and genotype distributions showed
statistically significant differences between SSA and LSA
patients (x2 = 20.84; p = 0.004 for haplotypes, and x2 = 35.9;
p = 0.0006 for genotypes). Haplotype A-A-G was more
common in LSA patients (14% v 0% in SSA; Fisher’s two
tailed exact test, p = 0.000075) and haplotype A-G-G in SSA
(69.7% v 46.4% in LSA; x2 = 16.3; p = 0.000041). TDT
confirmed the preferable transmission of the haplotype
A-G-G in the SSA group (table 7).
Although parents were only available for seven LSA
patients, TDT results showed a statistical trend towards the
transmission of A-A-G in this group. It is likely that the TDT
values did not reach statistical significance in LSA patients
owing to the small sample size analysed. However, as our
patients and controls are ethnically matched, there is little
distortion of the data obtained by EH, and the significance
reached by case–control standard statistics accurately reflects
the trends observed.
The results obtained in this three-loci haplotype analysis
suggest that while both allele A of c135G.A(A45A) and
allele G of c2307T.G(L769L) are associated with
Hirschsprung’s disease independently of the severity of the
phenotype, allele A of c1296G.A(A432A) in combination
with the variant alleles of c135G.A(A45A) and c2307T.
G(L769L) is associated with the more severe form of
Hirschsprung’s disease.
Two-loci haplotype
To determine whether the association found for
c1296G.A(A432A) was driven by the other polymorphic
alleles associated with Hirschsprung’s disease, three two-loci
haplotype distributions—c135G.A (A45A)-c2307T.G(L769L),
c135G.A(A45A)-c1296G.A(A432A), and c1296G.A(A432A)-
c2307T.G(L769L)—were compared between LSA and SSA
patients. As expected, for the combination c135G.
A(A45A)-c2307T.G(L769L), no difference between SSA
and LSA patients was found. However, significant differ-
ences in the global genotype and haplotype distributions
between LSA and SSA patients were observed for the
combination (c135G.A)A45A-c1296G.A(A432A) (x2 = 19;
p = 0.0012 for genotypes and x2 = 12.64; p = 0.0054 for
haplotypes), and the combination c1296G.A(A432A)-
c2307T.G(L769L) (x2 = 18.9; p = 0.001 for genotypes, and
x2 = 13.08; p = 0.0044 for haplotypes). In particular, for
c135G.A(A45A)-c1296G.A(A432A), haplotype A-G was
predominant in SSA patients (73% v 49% in LSA;
x2 = 12.11; p = 0.0005) and this was confirmed by TDT
Table 5 Comparison of haplotype frequencies between patients with Hirschsprung’s disease and controls, and results of
haplotype analysis using the transmission disequilibrium test
A45A A432A L769L
Frequencies estimated by EH TDT
c135G.A c1296G.A C2307T.G Controls (n = 100) All patients (n = 87) p Value TR NT x2 p Value
A G G 0.372 0.660 0.009 43 9 22.23 0.000002
G A T 0.164 0.052 0.01 3 16 8.89 0.0028
G G T 0.322 0.147 0.03 7 27 11.76 0.0006
A A G 0.009 0.021 .0.05 3 2 0.20 0.65
A A T 0.004 0.011 .0.05 0 1 1.00 0.32
A G T 0.024 0.037 .0.05 1 2 0.33 0.56
G A G 0.032 0.036 .0.05 4 4 0.00 1.00
G G G 0.071 0.035 .0.05 4 4 0.00 1.00
EH, linkage utility program; NT, chromosomes not transmitted; TDT, transmission disequilibrium test; TR, chromosomes transmitted.
Table 6 Allele frequencies (%) of the most frequent RET polymorphisms in SSA and LSA
patients and in patients with and without mutation in RET
Codon SNP (allele)
Sporadic cases of Hirschsprung’s disease
LSA (n = 14) v SSA (n = 73)
Without mutation (n = 71) v with
mutation (n = 16)
A45A c135G.A (A) 67.8 v 73.9 (x2 = 0.45, p = 0.50) 70.4 v 84.3 (x2 = 2.6, p = 0.10)
A432A c1296G.A (A) 25 v 9.5 (x2 = 5.26, p = 0.02) 12.6 v 15.6 (x2 = 0.47, p = 0.50)
L769L c2307T.G (G) 78.5 v 74.6 (x2 = 0.19, p = 0.66) 87.5 v 64.8 (x2 = 2.9, p = 0.08)
LSA, long segment aganglionosis; SNP, single nucleotide polymorphism; SSA, short segment aganglionosis.
Table 7 Results of haplotype analysis on LSA and SSA triads using the transmission disequilibrium test
A45A A432A L769L
TDT (7 LSA trios) TDT (45 SSA trios)
c135G.A c1296G.A c2307T.G TR NT x2 p Value TR NT x2 p Value
A G G 5 1 2.67 0.10 38 8 19.57 0.00001
A A G 3 0 3.00 0.08 0 2 2.00 0.15
A A T 0 0 – – 0 1 1.00 0.31
A G T 0 0 – – 1 2 0.33 0.56
G A G 1 1 0.00 1.00 3 3 0.00 1.00
G G G 2 0 2.00 0.15 2 4 0.67 0.41
G A T 0 2 2.00 0.16 3 14 7.12 0.007
G G T 0 7 7.00 0.008 7 20 6.26 0.41
LSA, long segment aganglionosis; NT, chromosomes not transmitted; SSA, short segment aganglionosis; TR, chromosomes transmitted.
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done in 45 SSA trios (TR:NT 38:8; x2 = 19.57; p = 0.00001).
Haplotype A-A was significantly more common in LSA
patients (18% v 0.8% in SSA; x2 = 17.37; p = 0.000031).
As for pair c1296G.A(A432A)-c2307T.G(L769L), the
most dramatic difference between SSA and LSA was that of
the haplotype A-G (1.5% in SSA v 24% in LSA; x2 = 22.8;
p = 0.000002). Haplotype G-G was significantly overrepre-
sented in the SSA group (73% v 53%, x2 = 8.6; p = 0.003). TDT
done in the SSA group also showed that G-G was preferably
transmitted (TR:NT 38:9; x2 = 17.89; p = 0.00002).
Two-loci haplotype analysis confirmed that allele A of
c1296G.A(A432A) in cis combination with either allele A of
c135G.A(A45A) or allele G of c2307T.G(L769L) is asso-
ciated with LSA.
Two- and three-loci haplotype distributions showed no
differences between patients with RET mutation and patients
without (data not shown).
RET-SNPs and RET haplotypes in other populations
Except for allele A of c1296G.A(A432A), those polymorphic
alleles associated with Hirschsprung’s disease in Chinese
patients (in particular allele A of c135G.A(A45A) and allele
G of c2307T.G(L769L)) are also associated with the disease
in white patients. However, the RET-SNP frequencies found
in our population (in both patients and controls) differ
considerably from those reported for the same SNPs in white
subjects (table 2). For instance, the frequency of allele A of
c135G.A(A45A) varied greatly between Chinese and white
control populations (41% v 16–23%, respectively) but
remained rather similar for the two patient populations
(73% in Chinese v 59–73.4% in whites). Allele G of
c2307T.G(L769L) occurred much more often in Chinese
patients (75.2%) than in white patients (30.5%–42.7%). In
addition, while the frequencies of the variant alleles of
c135G.A(A45A) and c2307T.G(L769L) were similar in the
Chinese population (patients and controls), they differed
greatly in white subjects (table 2). As to the
c2508C.T(S836S) polymorphism, the variant allele T was
not found either in patients or controls. In whites,
c2508C.T(S836S) is characterised by the low frequency of
the allele T in patients with Hirschsprung’s disease and its
overrepresentation in medullary thyroid carcinoma.33 38–40
The ethnic differences observed in the SNP frequencies
were reflected in the frequencies of the RET genotypes/
haplotypes associated with Hirschsprung’s disease.
Genotypes and haplotypes encompassing the same SNPs
were compared with those previously reported in the only
RET haplotype study done in white (Spanish) patients with
Hirschsprung’s disease (table 4).30 While 50.6% of the
Chinese patients shared the same genotype—genotype 1;
homozygous for both allele A of c135G.A(A45A) and allele
G of c2307T.G(L769L) and wild-type for the rest of
polymorphisms found—five different genotypes (BB, BC,
BD, BH and CD) together accounted for a similar number
(48%) of Spanish patients. In addition, those four genotypes
were rare in our patient population—that is, the most
common Hirschsprung’s disease genotype in Spanish people
(BB) is not observed in the Chinese. Furthermore, the most
common Hirschsprung haplotype seen in Chinese people
(A-G-G; 66%; c135G.A(A45A), c1296G.A(A432A),
c2307T.G(L769L); table 5) was only seen in 19% of the
Spanish patients; vice versa, the most common Hirschsprung
haplotype in Spaniards (30.7%; haplotype B: allele A of of
c135G.A(A45A) and wild-type for the other sites) was only
seen in 3.7% of the Chinese patients. Genotypes and
haplotypes comprising both allele A of c135G.A(A45A)
and allele G of c2307T.G(L769) are particularly associated
with Hirschsprung’s disease in Chinese people, while in
whites the main genotype and haplotype associated with
Hirschsprung’s disease comprise only allele A of
c135G.A(A45A).
DISCUSSION
The current data on Hirschsprung’s disease indicate that RET
haplotypes associated with this condition can themselves be
functional and lead to a low penetrance loss of function, act
as modifiers of the phenotype conferring risk/protection to
disease (additive/combinatorial effect of multiple RET poly-
morphisms, combinatory hypothesis), or represent linkage
disequilibrium with a low penetrance susceptibility locus. We
initiated this study to evaluate the RET ‘‘risk’’ haplotypes
present in our population, to elucidate the molecular basis of
Hirschsprung’s disease. We hypothesised that if the
Hirschsprung’s disease phenotype is related to the particular
combinations of RET-SNPs, and if the incidence of those
polymorphic variants differs among populations, identifica-
tion of those population specific SNPs and haplotypes
contributing to disease would definitely help in the discovery
of the molecular basis underlying Hirschsprung’s disease.
Our data showed that Chinese patients with
Hirschsprung’s disease are mainly represented by one RET
haplotype (comprising variant alleles of c135G.A(A45A)
and c2307T.G(L769L)), indicating that if this haplotype was
itself functional, 66% of the Chinese patients would share the
same genetic aetiology. The existing data on white patients
with Hirschsprung’s disease show that the haplotype
distribution is more diverse and that c135G.A(A45A) alone
is driving a strong association between haplotypes containing
this polymorphism (allele A) and Hirschsprung’s disease.
Those differences between populations in the frequencies of
the RET haplotypes with the best evidence for an association
with Hirschsprung’s disease suggest that the true RET disease
susceptibility allele remains to be identified; alternatively
they might suggest that different haplotypes in different
populations confer risk of or protection against disease, and
those ‘‘functional haplotypes’’ would also account for the
patients with Hirschsprung’s disease with no mutations in
any of the Hirschsprung genes.
In favour of the first explanation, it has been suggested
recently that in Spaniards,31 RET ‘‘risk’’ haplotypes appeared
to be in linkage disequilibrium with a putative founding low
penetrance susceptibility locus, located upstream of
c135G.A(A45A). Thus it could be that the ‘‘true’’ suscept-
ibility locus’’ is on different haplotype backgrounds because
of human population and history and structure, explaining
the differences found in the RET haplotypes associated with
Hirschsprung’s disease. The main RET haplotype associated
with Hirschsprung’s disease in Chinese people still belongs to
the group of haplotypes in linkage disequilibrium with the
low penetrance susceptibility locus upstream of A45A, as
previously described in whites.31 The differences in ‘‘risk
haplotype’’ frequencies between Chinese and whites could
indicate that recombination events within the region flanked
by A45A and L769L may have occurred (after the European–
Asian split). This may have originated in two ‘‘risk
haplotypes,’’ one mainly represented by allele A of A45A,
more common in Europeans, and another, more common in
the Chinese, represented by the variants alleles of A45A and
L769L. Both haplotypes could be in linkage disequilibrium
with the low susceptibility locus upstream A45A previously
described.31
The second explanation is not mutually exclusive with the
presence of a putative locus in linkage disequilibrium with
RET ‘‘risk’’ haplotypes, because particular combinations of
SNPs on those haplotypes could also act as modifiers.30 40
We also found that allele and haplotype distributions
varied with the severity of the Hirschsprung phenotype: allele
A of c1296G.A(A432) in combination with the variant
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alleles of c135G.A(A45A) and c2307T.G(L769L) was
associated with the more severe form of Hirschsprung’s
disease, while both c135G.A(A45A) and c2307T.G(L769L)
polymorphisms were associated with Hirschsprung’s disease
independently of the severity of the phenotype. However,
these data should be viewed with caution until further proof
is provided by functional analysis.
Differences in allele frequencies between different
Hirschsprung phenotypes have never been reported for
c1296G.A(A432A). Instead, in a study of 76 white patients
from Germany,32 differences in the frequency of allele A of
c135G.A(A45A) were found between SSA and LSA patients,
and also between patients with the RET mutation and those
without. It was also shown that c135G.A(A45A) poly-
morphism can modify the phenotype through a within-gene
interaction. In our series c135G.A(A45A) was not associated
with any Hirschsprung phenotype or with RET mutations.
Instead, c1296G.A(A432A) and haplotypes comprising it
were associated with the more severe form of the disease. No
differences were found in allele and haplotype distributions
when patients harbouring or not harbouring the RET
mutation were compared, which could indicate that RET
specific haplotypes may influence the Hirschsprung’s disease
phenotype regardless of the RET mutation status. This
influence could be through interaction of the RET-SNPs
within RET itself or with other genes.
RET haplotypes containing the allele T of c2508C.
T(S836S) have a protective role in the pathogenesis of
Hirschsprung’s disease.33 40 This allele has not been found in
the Chinese, so there is ethnic variation in the polymorph-
isms implicated in the phenotype modulation of Hirsch-
sprung’s disease and possibly medullary thyroid carcinoma.
Interestingly, differences in the distribution of the RET
haplotypes have also been detected among patients with
papillary thyroid carcinoma from different white populations.41
Transmission of mutations in other Hirschsprung genes
(EDRNB, GDNF) has been found to be associated with the
transmission of RET polymorphisms, proving the genetic
interaction underlying Hirschsprung’s disease.24
Combinations of variants in several components of the RET
and EDRNB signalling pathways might overall provide an
important risk factor for disease susceptibility and also
contribute to the necessary response to produce the
Hirschsprung phenotype. When a candidate gene contains
various polymorphisms, these are usually in linkage dis-
equilibrium because the relatively small genetic distances
make it difficult in a single population to dissect out the
important polymorphism. Ethnic differences in the haplo-
types associated with disease can make it easier to isolate the
SNP that actually confers susceptibility to a given disease at a
given locus. Thus our data are highly relevant to
Hirschsprung’s disease risk and to gene mapping, particularly
for genome-wide testing for linkage disequilibrium through
the use of SNP markers.
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